Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$85.65 USD

85.65
493,550

+2.10 (2.51%)

Updated Aug 7, 2025 04:00 PM ET

Pre-Market: $85.65 0.00 (0.00%) 8:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

by Zacks Equity Research

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Zacks Equity Research

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

Zacks Equity Research

Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets

by Zacks Equity Research

Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.

Zacks Equity Research

Abbott's (ABT) New Pact to Advance Clinical Trials Diversity

by Zacks Equity Research

Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.

Zacks Equity Research

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Zacks Equity Research

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.

Zacks Equity Research

Here's Why You Should Retain Patterson Companies (PDCO) Stock Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Zacks Equity Research

NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.

Zacks Equity Research

Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations

by Zacks Equity Research

Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.

Zacks Equity Research

Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Zacks Equity Research

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

Zacks Equity Research

DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.

Zacks Equity Research

Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Zacks Equity Research

McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.

Zacks Equity Research

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.

Zacks Equity Research

QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.

Zacks Equity Research

BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.

Zacks Equity Research

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

Zacks Equity Research

Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.

Zacks Equity Research

Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up

by Zacks Equity Research

Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.

Zacks Equity Research

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.

Zacks Equity Research

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.

Zacks Equity Research

Merit Medical (MMSI) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Merit Medical (MMSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Merit Medical Systems, Inc. (MMSI) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.